Abstract: Exercise-induced bronchoconstriction (EIB) can be a troublesome problem in asthmatic children and in some children withoutasthma.Self-reportedexerciserelatedsymptomsshouldbeverifiedformally.EIBismediatedbychangesintemperatureand humidityintheairwayandissecondarytoreleaseofseveralmediatorsofthebronchoconstrictionincludingleukotrienes.Montelukast asaleukotrienereceptorantagonistoffersprotectionagainstbutdoesnotcompletelyameliorateEIB.Regularusedoesnotappearto leadtotolerance.Nightmares,abdominalpain,fever,nauseaandaggressivenessarecommonlydescribedsideeffects;however,the overallsafetyprofileofmontelukastisgoodanddoesnotchangewithlongtermuse.Thereareindividualdifferencesinresponseto montelukastforprotectionagainstEIB.Bronchoconstrictiontriggeredbyexerciserespondstocessationofexerciseinitsnaturalcourse. Duetoitspharamacokineticprofile,montelukastmaybemoreusefulasaprophylaxisthantorelievesymptoms.
Asthma is a chronic inflammatory disorder of the airways in whichmanycellsandcellularelementsplayarole.Thechronic inflammation is associated with airway hyperresponsiveness (AHR) that leads to recurrent episodes of wheezing, breathlessness, chest tightness and cough particularly at night or in the early morning. These symptoms are usually associated withwidespreadbutvariableairflowlimitationwithinthelung that is at least partly reversible either spontaneously or with treatment. 2 Thisdefinitionhighlightsthetwounderlyingcardinal pathophysiological factors of asthma. These include airway hyperresposiveness leading to intermittent airflow limitation and airway inflammation. Breathlessness and wheezing secondary to airflow limitation is experienced by asthmatic subjects in responsetovariousstimuliincludingexerciseandis anindicationofAHR.TheGreekphysicianAretaeus offers the first description: "If from running, and exercise,andlaborofanykindadifficultyofbreathingfollowsitistermedasthma". Exercise-induced asthma (EIA) and exerciseinduced bronchoconstriction (EIB) are terms that are often used interchangeably in literature. The term exercise-induced asthma (EIA) is imperfect as it impliesthatexercisecausesasthma,ratherthanbeing atriggerthatexacerbatesit.EIBisamoreaccurate description. 4 EIB is common in persons with clinicalsignsandsymptomsofasthma,butitalsooccurs inpersonswhodonothaveclinicalsignsandsymptoms.A10%-15%dropinforcedexpiratoryvolume in 1 second (FEV 1 ) from pre-exercise levels after 20-30minutesofexerciseisdefinedasEIB. 5 For the purposes of this review, EIA and EIB will be used interchangeably.
Diagnosis of EIB
Self-reported symptoms of dyspnoea, increased effort or work to breathe, chest tightness, shortnessofbreath,wheezingorcoughwithexerciseare suggestive of EIB. 6 This needs to be confirmed by objective testing as not all exercise related breathlessnessisEIBandclinicalsignsandsymptomsare notgoodpredictorsofbronchoconstriciton. 6, 7 Only 8outof52(15.4%)childrenreferredforpoorlycontrolledEIAfulfilledcriteriaforEIAwhenformally testedintherespiratorylaboratory, 8 and only 8 out of 39 (20.5%) patients evaluated by cardiopulmonaryexercisetestinginadultshadEIB. 9 It is important to be aware that exercise-induced symptoms couldmaskavarietyofotherdiseasesorconditions, such as poor physical fitness, vocal cord dysfunction(VCD),exercise-inducedparadoxicalarytenoid motion (EPAM), exercise-induced laryngomalacia (EIL),exercise-inducedhyperventilationandhypertrophic cardiomyopathy or arrhythmias with long Q-wavetoT-waveintervalQT. 10 Thetimingofthe appearance of breathlessness in relation to exercise canprovidesomeclueaboutanalternativediagnosisasthenadirofEIBhappens5to10minutesafter vigorousandsustainedexercise, 11 as opposed to the shortnessofbreathexperiencedduetoalackoffitnessorpre-existingairflowlimitationwhereshortnessofbreathdevelopsduringexercisebutimproves afterwards.
The diagnosis of EIB is confirmed by changes in pulmonary function after bronchial provocation. Pragmatically, the provocation test used most commonly is exercise. A fall in FEV 1 of 10%-15% or moreafteranexercisechallengeisusuallyconsidered suggestive.Exerciseprotocolsbasedonachievement ofspecificphysiologicalparameterssuchasheartrate are usually used. Treadmills or bicycle ergometers canbeusedtoachieveexerciseendpoints.Theexerciseloadneedstobehighasassessedviaheartrate, and the test should be standardized with respect to environment temperature and humidity. ThisapproachtothediagnosisofEIBmayneedto bemodifiedinathletes.Subjectsmayberequiredto betestedintheirusualenvironment(sportspecific)at times.Surrogateprovocationtestshavebeenusedand areacceptedbysportsbodiesindiagnosisofexercise induced asthma. There may be advantages to using surrogate tests, especially when evaluating children and elderly or obese adults.
Hyperventilation with dry cold air (eucapnic hyperventilation) is also used instead of exercise as astimulusforEIB.Thisisaphysicallydemanding testandrequirestheathletetoperformhyperpnoea byinhalingaircontaining5%carbondioxideatven-tilation equivalent to 30 times the baseline FEV 1 .
Hyperosmolaraerosolslikemannitoland hypertonic saline are other indirect stimuli for bronchial provocation tests. Eucapnic voluntary hyperpnea (EVH)isasensitivetestespeciallyforeliteathletes but there are some concerns about safety. In asthmaticsandnonathletes,hyperosmolaraerosolsmayoffer practical advantages over EVH or exercise testing. Mannitolinparticularisavailableasasimplestandardizedsingleusekit.
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Mechanism of EIB
Hyperpnoeainresponsetoexercisecausesnetwater lossfromtheairwaysurface.Thisdryingappearsto triggerEIB by changesinosmolalityof theperciliarylayeroffluid,leadingtobronchialepithelialcell shrinkage and release of inflammatory mediators.
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Anderson
14 suggeststhatEIBappearstobeanexaggerated response to airway dehydration in the presenceofinflammatorycellsandmediatorsinaperson with a responsive bronchial smooth muscle.
Several mediators are likely to contribute to EIB including prostaglandin (PG) D 2 , leukotriene (LT) C 4 , adenosine and histamine, and in turn different cell types including mast cells, eosinophils, sensory nerves and epithelial cells are mediator sources. Drugs that inhibit the release of mast cell mediatorsorpreventthebronchoconstrictoreffects, or reduce the production of mediators or mast cell numberhavebeenshowntohavebeneficialeffects on EIB.
5 9α,11β-PGF 2 , a metabolite of PGD 2 can be detected with the help of sensitive assays in the urine and sputum of asthmatics and athletes with EIB.
5 Asignificantassociationbetweenchangeinits levelsfrombaselineandpercentagechangesinFEV 1 indicate that PGD 2 is likely to be the most importantmediatorofEIB.Inhealthysubjects,PGD 2 and LTE 4 are100and1,000timesaspotentashistamine or methacholine in provoking bronchoconstriction, respectively.Asingleclassofreceptorsinhumanairway smooth muscle appear to mediate contractions inducedbyLTC 4 ,LTD 4 andLTE 4 .
15 ThecysteinylLT 1(cysLT 1 ) receptor is a G-protein-coupled receptor thatisexpressedinperipheralbloodleukocytesand othertissues.Themajorintracellularsignalingpathway for the cyLT1 receptor is via calcium release. CysLT receptor antagonists (CysLTRAs) block the actions of cysteinyl-leukotrienes at this receptor ontargetcells. 16 HencemontelukastasaCysLTRA has found a place in the therapeutic armamentarium againstEIB.
Metabolism and Pharmakokinetic Profile
Thepharmacokineticprofileofmontelukasthasbeen extensivelystudied,andthereisamultitudeofdata identifyingthepathwayofthedrugduringits activity in vivo. Such studies have been performed within paediatric populations in addition to adults to support its appropriate and safe use in both populations. Montelukastisapotent,orallyactiveselectiveleukotriene receptor antagonist (LTRA) that is rapidly absorbedfollowingadministration.
17-21 Thedifferent formulations of tablet (chewable tabletandgranules) havebeenshowntohavedifferingbioavailabilities. Consequently,peakplasmalevelsarereachedatdifferent rates.
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A 10 mg dose in adults has been shown to have an oral bioavailability of 64% and achieves a peak plasma concentration (C max )within3-4hours(T max ) with no effect on administration prior to or after a meal. [18] [19] [20] [21] The5mgchewabletablet achieved a C max in 2-2.5hoursanddemonstratedabioavailabilityof73% (fasted)and63%(postmeal). [18] [19] [20] [21] The4mg chewable tablet and 4 mg oral granules are bioequivalent to the 5 mg chewable tablets, but a C max is achieved within2hours.However,amealwithadministration reduced C max by35%,andprolongedT max by 1 hour and 2.9 hours for the chewable tablet and granules, respectively.
From the literature it is evident that montelukast is rapidly absorbed from the gastrointestinal tract and bioavailability is affected by formulation choice;however,plasmaconcentrationdiffersinthe youngest population of infant patients. The plasma concentration profile following oral administration to adolescents $ 15 years is similar to that seen in adults (10 mg dose). [22] [23] [24] The plasma concentration profilefollowingadministrationofthe4mgor5mg chewable tablets,inchildren2-5yearsor6-14years, isalsosimilartothatoftheadultsreceiving10mg tablets. Variability of plasma concentrations has been shown to be greater for the oral granules in infants 12-23 months than in adults and even more so in infantsof6-11months.
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Peak plasma concentrations are achieved at differentrates,butallformulationsareappropriatefor oncedailydosing,astherapeuticeffectspersistforat least24hoursinalldemographics. [22] [23] [24] Montelukast ismorethan99%protein-boundwithminimaldistributionacrosstheblood-brainbarrier, 25 and is extensivelyhepaticallymetabolized, [22] [23] [24] specificallybythe cytochrome P450 (CYP) enzymes. Earlier studies identified that metabolism predominantly involved the3A4,2A6and2C9microsomes; 25 however,more recent studies have shown more involvement by the 2C8 microsomes. 26 In addition, metabolism occurs via the acyl glucuronidation pathway within the gastrointestinal tract.
26 At a therapeutic dose, montelukastdoesnotinhibittheCYPenzymesandthereforewillnotaffectotherdrugsadministeredthatare metabolizedbythesamehepaticpathway.However, when administering montelukast with known CYP 3A4inducers,suchasrifampicinandphenytoin,care shouldbetaken.
Clinical Use
Role of montelukast specifically in EIB Aswellastheabovementionedindicationsfortheuse ofmontelukastinwheezingdisorders,therehavebeen severalstudiesoverthelast15yearsspecificallylooking attheeffectivenessofmontelukastinprotectingagainst EIB in older children and adolescents. Leukotrienes areimplicatedinsustainingabronchoconstrictiveand inflammatoryresponseinEIB. Consequently,leukotriene inhibition is an attractive option to consider for EIBtreatment.Thisreviewwillfocusonstudiesthat examined paediatric populations.
Montelukastmaystartactingwithin2hoursoforal administration, unlike Beta-2 (β2) agonists, which have an instantaneous effect.This effect reaches its maximum by 12 hours after administration and persists for up to 24 hours. 29, 30 Bronchoconstrictiontriggeredbyexerciserespondstocessationofexercisein its natural course. Due to its pharamacokinetic profile,Montelukastmaynotbetheoptimalmedication forreliefofsymptoms,butmaybemoreusefulwhen givenasaprophylaxis. Severalstudieshavelookedatthelongtermuse ofmontelukast. [31] [32] [33] [34] Montelukastimprovesthemagnitude of bronchoconstriction and is significantly protectiveinEIB.Protectionismeasuredasthemagnitude of post-exercise fall in FEV 1 ,aswellasmaximal decrease in FEV 1 with exercise. [31] [32] [33] [34] It also shortens the time to recovery of FEV 1 topre-exerciselevel, [31] [32] [33] [34] and in some children it also improves the late phase response to exercise. 32 This protective response is evident even after a few days of prophylaxis with montelukast. 31 The response is sustained for the duration of montelukast prophylaxis uniformly in allstudies,butthelengthoftimeforwhichthisprotection persists is variable. Leff 35 showednolasting protection2weeksafterstoppingmontelukast;however,inapaediatricstudyof6-14yearolds,Kim 33 showed that improvements in asthma symptom scores were present even after 8 weeks of discontinuingmontelukast.
The other beneficial property of montelukast is that no tolerance develops to its effect when given
The Current clinical use of montelukast for wheezing disorders is as follows:
Age range Clinical setting
Step in guidelines Marketing authorisation as a prophylaxis, as compared to β2 agonists for a prophylaxis.
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Timing-of-day dosing of montelukast in relation to its protective effect has also been studied. Pajaron-Fernandez 36 lookedatEIBafter2weeksof morningoreveningdoseofmontelukastandfound nodifferencewhethermorningoreveningdosewas used.
Theseprotectiveeffectsappeartobeindependent of concomitant use of inhaled corticosteroids.
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However, unlike β2 agonists, protection from EIB is not complete (eg, 59% reduction in the study by Kempandcolleagues 31 ),andaproportionofpatients maybenon-responderstomontelukast. 
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Specifically in EIB, Kim 37 looked at the effect of genetic polymorphisms of the Thromboxane A 2 receptor on the efficacy of montelukast in EIB in Korean children. They identified certain polymorphisms (TBXA2R + 924T . Chomozygote, TBX2AR795T . Chetero-andhomo-zygote)hada threefoldpoorresponseto8-weekmontelukasttreatment with respect to maximum percent fall in FEV 1 after exercise, in comparison to patients with more common alleles.
Overall the evidence supports improvement in EIBwithmontelukastonly,thoughthisimprovement isnotcomplete.Theprotectionseemstolastaslong asmontelukastistakenregularlywithoutappearance of tolerance, 33, 34 but this protection disappears after stopping montelukast in some studies. 34 The availableevidencesupportstheuseofregularmontelukast treatment for children where EIB is the main manifestation of their asthma.
Montelukast Compared to Other Therapies in EIB Short acting B2 agonists
TheimprovementintheextentofEIBafterinhaled β2 agonist use is almost complete, as compared to montelukast, with which the response is modest.
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Additionally, a problem alluded to earlier involves theheterogeneityinresponsetoMontelukastascompared to inhaled β2agonists. 
Long acting Beta2 agonists
Inhaled steroids
Vidal and colleagues
43 compared montelukast to budesonidein20patientswithEIA.Patientsreceived 10mgofmontelukastoncedailyfor3dayscompared to400mcgofbudesonidetwicedailyfor15days,with a15-dayinterveningwashoutperiod.Both therapies showed significant improvement as compared to baseline.However,therewereconsiderable individual variations in response to both medications. 43 The study concluded with the recommendation that both medications be tested in each patient prior to the finaldecision. Montelukast plus loratadine did not result in significant additive bronchoprotective effects on eIB. Exercise-induced bronchoconstriction was significantly diminished after 4 weeks in all active treatment groups compared with placebo. Budesonide + Montelukast were significantly superior to other treatment options.
Fish oil
StudiescomparingLTRAstosomeothermedicationorcombinationsaresummarizedinTable 1.
Montelukast is at least similar to long acting β 2 agonists (LABAs) in the amelioration of EIB in the short term 39 and affords better protection than LABAs in the long term. [40] [41] [42] Concerns over tolerance to LABAs would make montelukast a more suitabledrugtobeusedintheongoingmanagement of asthmatic patients where EIB is a troublesome manifestation of their asthma. Even when LABAs are combined with inhaled corticosteroids (ICS), montelukast is superior for the protection against EIB. 46, 47 The protection afforded by montelukast is not as complete as with SABA, 38 though the latter works only for a short duration compared to montelukast.
Safety and Tolerability
Adversedrugreactions(ADR)areacommonconcern whenprescribingtreatments.Brunlofand colleagues 48 reviewedsafetyreportsfornumerousdrugsadministered to children and identified LTRAs having the greatest number of concerning reports. The ADRs reported(suchasnightmares,abdominalpain,fever, nausea and aggressiveness) are all considered in the manufacturer's summary of product characteristics; [17] [18] [19] in addition, this review identified the potential need for further exploration of psychiatricADRs in those childrentakingmontelukast.
Montelukast is currently used widely in paediatrics and it is important to discuss the appropriatesafeuseofthedrugfortherapy.Areviewwas carriedoutbyBisgaardandcolleagues 49 of numerousdouble-blind,placebo-controlledtrialsofmontelukast in addition to the following open-label extension studies with data from 2751 patients aged6monthsto14years,diagnosedwithallergic rhinitis,persistentasthmaandintermittentasthma. Theoverallinferencewasthatthesafetyprofileof montelukastinthesegroupsofpatientswasnotsignificantlydifferentfromplacebo,nordiditchange withlongtermuse.
Studieswithmontelukasthaveidentifiedmorespecific tolerability and safety profiles within different demographics. In particular, appropriate dosing has been tested in various studies in hopes of reducing anyrisksthatmayarisefromselectingmontelukast as a therapy for children. Useofmontelukastininfantsaged6to24months isdocumentedtobewell-toleratedatadoseof4mg. 50 Significantly comparable pharmacokinetics were observedinthisgroupofinfantswhencomparedto adultsreceivinga10mgdose. 50 Thisis furtherreinforcedbyevidencefromastudyinvolvingchildren aged6to24monthswithasthma,inwhichpatients received the same 4 mg dose of treatment. 51 There wasnosignificantdifferenceinclinicaladverseexperiencesfoundintheactivetreatmentgroupcompared to placebo and overall this group of patients toleratedmontelukast4mggranuleswellforaperiodof sixweeks.
Safe use was further evaluated in infants 1-3monthsold 50 and3-6monthsold. 52 Interestingly, inasmallstudyof1-3month-oldinfants(N=12), the area under the curve concentration was found to be 3.6 times higher than the value for 6-24 month oldinfants.Despitethis,atatesteddoseof4mgand 8mgtherewerenodrug-relatedadverseexperiences andthedrugwaswell-toleratedoverall. 50 Astudyinvestigatingasafedoseforchildrenaged 2-5yearsdeterminedthata4mgdoseofmontelukast waspreferabletoadoseof5mg. 53 Thisfindingwas further confirmed by a similar study comparing the pharmacokineticsinthissameagegroup,comparedto adultpharmacokinetics. 54 Ingroupsofolderchildren from6 yearsto14 years,itwasfound thatpatients receiving montelukast did not have significantly higheradversereactions(drug-andnondrug-related) thanplacebo.Therefore,atolerabilityandsafetyprofilesimilartoplacebowasdeterminedforbothshorttermandlong-termuseofmontelukast.
55,56
Patient Preference
In a study comparing attitudes toward montelukast andinhaledcromolyn,parentandpatientpreference, parent and patient satisfaction, and patient adherence to therapy were all significantly better with oral montelukast compared with inhaled cromolyn. β2agonistusewasdecreasedwhentakingmontelu-kast, which was safe and well-tolerated. 57 Similarly in an open-label study comparing montelukast and beclomethasone, 58 parentsreportedthatmontelukast wasmore convenient,lessdifficulttouseandwasused as instruct ed more often as compared to beclomethasone.
However, in another study 59 comparing fluticasone to montelukast in asthmatic subjects, significantly more patients were satisfied with fluticasone compared to montelukast. Hence, it is difficult to draw any conclusive inference of patient preference for montelukastoverothertreatments.Wewerenotable to identify any studies which specifically looked at patient preference for use of Montelukast in treatment of EIB.
Conclusions
In conclusion, exercise-induced bronchoconstriction ismediatedbychangesintemperatureand/or humidity inthepresenceofinflammatorycellsintheasthmatic airway,andissecondarytoreleaseofseveralmediatorsofbronchoconstriction.Leukotrienesareamajor groupofmediatorscausingbronchoconstriction,and regularorintermittentuseofmontelukastoffersprotection against EIB; however, this protection is not complete. Regular use does not appear to lead to tolerance.Thereareindividualdifferencesinresponse tomontelukastforprotectionagainstEIB.Nightmares, abdominal pain, fever, nausea and aggressiveness are the commonly described side effects; however, theoverallsafetyprofileofmontelukastisstillvery goodanddoesnotchangewithlong-termuse.There issomeevidencetosuggestthatpatientspreferthis oral therapy to inhaled medications. 
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